Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia

Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernando, Emmaline Zantua, Yu, Jeryl Ritzi Tan, Santos, Salvador Miclat Abad, Jamora, Roland Dominic Go
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorder Society 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840242/
https://www.ncbi.nlm.nih.gov/pubmed/33278866
http://dx.doi.org/10.14802/jmd.20091
Descripción
Sumario:Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Ejemplares similares